Melanoma Institute Australia shines at prestigious Cancer Research Awards
3 November 2018
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
Professor Georgina Long, Co-Medical Director of Melanoma Institute Australia, has won the top award for Outstanding Cancer Researcher of the Year. One of the world’s pre-eminent melanoma clinicians and researchers, Professor Long has changed the face of melanoma treatment around the world with her ground-breaking clinical trials tripling life expectancy for patients with advanced melanoma and curing a significant subset.
Fellow MIA Co-Medical Director, Professor Richard Scolyer, has been awarded The Professor Rob Sutherland AO Make a Difference Award, which is awarded in recognition of lasting impact and sustained progress to cancer care or research practice. Professor Scolyer is the world’s leading melanoma pathologist, each year receiving more than 2,000 cases for review and opinion from around the world. He recently co-edited the new WHO Classification of Skin Tumours, 4th Edition.
Also awarded were MIA’s Associate Professor Alex Menzies, who won the Outstanding Cancer Research Fellow Award with less than five years post-doctoral experience in research, and Associate Professor Anne Cust, who was awarded Outstanding Cancer Research Fellow with more than five years post-doctoral experience in research.
Associate Professor Menzies is a Medical Oncologist with research interest in clinical trials of new systemic therapies for melanoma, biomarkers of response and resistance to systemic therapy, and immunotherapy-related toxicity. Associate Professor Cust is an epidemiologist whose research focuses on melanoma epidemiology, prevention, early detection and survivorship and has a strong emphasis on translational outcomes.
Melanoma Institute Australia CEO Matthew Browne said it was a proud moment to see Melanoma Institute Australia’s research and clinical team centre stage at the prestigious awards night.
‘This is well deserved recognition for not only these award winners, but also the multi-disciplinary teams across MIA that work tirelessly to develop new treatments to save lives from melanoma,’ Mr Browne said.
‘My particular congratulations go to Professor Long for taking out the prestigious Outstanding Cancer Researcher of the Year Award. This is testament to her research and global thought leadership which has set the world on the path towards advanced melanoma becoming a chronic disease rather than a terminal one.
‘She was gracious in acknowledging the award was recognition of the whole team’s efforts at MIA, and particularly her long research partnership with Professor Richard Scolyer.
‘With the breakthroughs in melanoma treatment also set to revolutionise treatments for other cancers, Professor Long’s legacy will potentially impact millions across the globe.’
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.